drugset / Trial / NCT04837209
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Phase 2
Active not recruiting
32 enrolled
Massachusetts General Hospital
Duke University · collabSibley Memorial Hospital · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Timeline
- Start
- 2021-07-21
- Primary completion
- 2027-02-01
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | — | Intravenous |
| Subject | Niraparib | Small molecule | — | Oral |